Imfinzi and BCG combination brings a major advancement for patients with high-risk early-stage bladder cancer
Wilmington, Delaware, 2 June 2026 – AstraZeneca has achieved a significant milestone in cancer care after receiving approval from the U.S. Food and Drug Administration (FDA) for its immunotherapy drug Imfinzi in combination with Bacillus Calmette Guérin (BCG) for the treatment of certain bladder cancer patients. The approval introduces a new treatment option for individuals with high-risk non-muscle invasive bladder cancer and marks an important step forward in the fight against the disease.
The FDA approval allows the use of Imfinzi, also known as durvalumab, together with BCG for adults whose cancer has not yet spread into the muscle layer of the bladder and who have not previously received BCG treatment. The decision is expected to benefit patients who face a high risk of disease recurrence and progression despite undergoing standard therapy.
Bladder cancer remains one of the most commonly diagnosed cancers worldwide, with non-muscle invasive bladder cancer accounting for a large percentage of cases. While BCG has been a standard treatment for decades, there has been limited innovation in this area, creating a need for more effective therapies that can improve patient outcomes and reduce the likelihood of disease progression.
The approval was supported by results from the Phase III POTOMAC clinical trial, which evaluated the effectiveness of combining Imfinzi with BCG. Study findings showed that patients receiving the combination therapy experienced a significantly lower risk of cancer recurrence, progression, or death compared with those treated with BCG alone. The results also demonstrated longer disease-free survival, highlighting the potential benefits of adding immunotherapy to standard treatment.
Industry experts view the approval as an important breakthrough because treatment options for high-risk non-muscle invasive bladder cancer have remained largely unchanged for more than three decades. Many patients often require repeated procedures and ongoing monitoring, while some eventually face bladder removal surgery if the disease advances.
The latest approval further strengthens AstraZeneca’s growing oncology portfolio. Imfinzi is already approved for multiple cancer indications, including lung and liver cancers, and continues to play an expanding role in the company’s cancer treatment strategy. The addition of bladder cancer broadens the drug’s reach and reinforces AstraZeneca’s commitment to developing innovative immunotherapy solutions.
The approval also reflects the growing importance of immunotherapy in modern cancer care. Unlike traditional treatments that directly target cancer cells, immunotherapies work by helping the body’s immune system identify and attack cancer more effectively. As research advances, these therapies are increasingly becoming a key part of treatment strategies across multiple cancer types.
Healthcare professionals believe the new treatment option could improve long-term outcomes for thousands of patients diagnosed with high-risk bladder cancer each year. With continued innovation in oncology and expanding use of immunotherapy, AstraZeneca’s latest achievement highlights the ongoing transformation of cancer treatment and the industry’s focus on delivering more effective and personalized care solutions.
